Summary of all biomarkers panels
| Panel | Components | Outcome | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| SteatoTest | α2-Macroglobulin, apo A1, haptoglobin, total bilirubin, GGT, BMI, cholesterol, triglycerides and fasting glucose | NAFLD (intrahepatic triglyceride content≥5.56%) | 73% (65%–80%) | 72% (58%–83%) | 87% (79%–92%) | 51% (40%–63%) |
| ActiTest | α2-Macroglobulin, apo A1, haptoglobin, total bilirubin, GGT, ALT | NASH | 74% (64%–82%) | 62% (53%–70%) | 60% (50%–69%) | 75% (66%–83%) |
| NashTest-2 | α2-Macroglobulin, apo A1, haptoglobin, total bilirubin, GGT, AST, cholesterol, and triglycerides | NASH | 71% (61%–80%) | 60% (50%–69%) | 59% (49%–68%) | 72%(61%–81%) |
| FibroTest | α2-Macroglobulin, apo A1, haptoglobin, total bilirubin, GGT | Advanced fibrosis (stage≥3) | 64% (42%–82%) | 73% (66%–79%) | 23% (14%–35%) | 94% (89%–97%) |
apo A1, apolipoprotein A1; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; GGT, γ-glutamyl transferase; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NPV, negative predictive value; PPV, positive predictive value.